Table 1.
Summary statistics for atezolizumab exposure simulated for various regimens
| Regimen | Cmax (90% PI), μg/mL | Cmin (90% PI), μg/mL | Weekly AUC (90% PI), μg·day/mLa |
|---|---|---|---|
| 1200 mg q3w | |||
| Cycle 1 | 403 (274–581) | 85 (55–133) | 1048 (763–1471) |
| Steady state | 610 (414–891) | 194 (89–383) | 2115 (1264–3507) |
| 840 mg q2w | |||
| Cycle 1 | 281 (187–420) | 74 (48–116) | 860 (617–1237) |
| Steady state | 517 (334–801) | 226 (118–426) | 2188 (1336–3733) |
| 1680 mg q4w | |||
| Cycle 1 | 563 (379–822) | 97 (58–159) | 1288 (887–1845) |
| Steady state | 759 (514–1106) | 182 (87–369) | 2217 (1357–3705) |
| 20 mg/kg q3w | |||
| Cycle 1 | 501 (378–665) | 107 (70–149) | 1305 (1002–1683) |
| Steady state | 753 (544–1038) | 238 (115–443) | 2596 (1592–4140) |
Geometric means with 90% PIs (for 500 patients) are shown
AUC area under the concentration–time curve, Cmax maximum serum atezolizumab concentration, Cmin minimum (trough) serum atezolizumab concentration, PI prediction interval, q2w every 2 weeks, q3w every 3 weeks, q4w every 4 weeks
aWeekly AUC over 3 weeks (for q3w regimens), over 4 weeks (for q4w regimen), and over 2 weeks (for q2w regimen)